Glycorex Transplantation AB (publ) (NGM:GTAB.B)
1.755
-0.015 (-0.85%)
At close: Nov 18, 2026
NGM:GTAB.B Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 34.43 | 38.84 | 35.16 | 29.96 | 36.12 | 28.2 |
Revenue | 34.43 | 38.84 | 35.16 | 29.96 | 36.12 | 28.2 |
Revenue Growth | -8.87% | 10.48% | 17.34% | -17.04% | 28.06% | 3.55% |
Cost of Revenue | 7.04 | 6.8 | 6.94 | 3.6 | 5.84 | 3.95 |
Gross Profit | 27.39 | 32.04 | 28.22 | 26.37 | 30.27 | 24.26 |
Selling, General & Admin | 30.92 | 30.08 | 29.34 | 36.94 | 32.31 | 29.23 |
Amortization of Goodwill & Intangibles | 3.42 | 3.42 | 3.42 | 3.42 | 3.68 | 3.76 |
Other Operating Expenses | -0.35 | -0.27 | -0.02 | -1.57 | -2.24 | -1.66 |
Operating Expenses | 39.56 | 39.11 | 38.64 | 44.32 | 38.63 | 36.07 |
Operating Income | -12.17 | -7.07 | -10.42 | -17.95 | -8.36 | -11.82 |
Interest Expense | -0.31 | -0.36 | -0.58 | -0.29 | -0.25 | -0.27 |
Interest & Investment Income | 0.04 | 0.04 | 0.15 | 0.3 | 0.02 | 0.01 |
Currency Exchange Gain (Loss) | -0.33 | -0.39 | -0.16 | -0.03 | 0.06 | -0.16 |
EBT Excluding Unusual Items | -12.78 | -7.78 | -11 | -17.98 | -8.52 | -12.24 |
Asset Writedown | - | - | - | -12.39 | - | - |
Pretax Income | -12.78 | -7.78 | -11 | -30.36 | -8.52 | -12.24 |
Income Tax Expense | -0.06 | -0.06 | -0.06 | - | 0.06 | 0 |
Net Income | -12.72 | -7.72 | -10.94 | -30.36 | -8.58 | -12.24 |
Net Income to Common | -12.72 | -7.72 | -10.94 | -30.36 | -8.58 | -12.24 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 79 | 78 | 74 | 74 | 74 | 74 |
Shares Outstanding (Diluted) | 79 | 78 | 74 | 74 | 74 | 74 |
Shares Change | 3.55% | 5.93% | - | - | - | 0.36% |
EPS (Basic) | -0.16 | -0.10 | -0.15 | -0.41 | -0.12 | -0.17 |
EPS (Diluted) | -0.16 | -0.10 | -0.15 | -0.41 | -0.12 | -0.17 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 0.26 | 2.36 | 0.1 | -12.53 | -1.48 | -2.56 |
Free Cash Flow Per Share | 0.00 | 0.03 | 0.00 | -0.17 | -0.02 | -0.04 |
Gross Margin | 79.55% | 82.48% | 80.27% | 88.00% | 83.82% | 86.00% |
Operating Margin | -35.35% | -18.19% | -29.63% | -59.92% | -23.14% | -41.89% |
Profit Margin | -36.94% | -19.87% | -31.12% | -101.34% | -23.75% | -43.41% |
Free Cash Flow Margin | 0.75% | 6.07% | 0.29% | -41.81% | -4.10% | -9.08% |
EBITDA | -11.78 | -6.4 | -9.78 | -17.45 | -7.84 | -11.46 |
EBITDA Margin | -34.20% | -16.46% | -27.81% | -58.22% | -21.69% | -40.65% |
D&A For EBITDA | 0.4 | 0.67 | 0.64 | 0.51 | 0.52 | 0.35 |
EBIT | -12.17 | -7.07 | -10.42 | -17.95 | -8.36 | -11.82 |
EBIT Margin | -35.35% | -18.19% | -29.63% | -59.92% | -23.14% | -41.89% |
Revenue as Reported | 35.79 | 40.11 | 34.77 | 33.4 | 39.33 | 29.58 |